B
Bull
Bull · 25%MIST
$2.13
情景价格
$1.180
+0.041 (+3.51%)收盘时
Loading chart…
- High
- 1.185
- Open
- 1.140
- VWAP
- 1.17
- Vol
- 767.74K
- Mkt Cap
- 68.71M
- Low
- 1.140
- Amount
- 896.97K
- EV/EBITDA, TTM
- -0.11
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.
AI analysis of Milestone Pharmaceuticals Inc (MIST)
buyMilestone Pharmaceuticals Inc is a good buy right now due to its recent positive developments, including a pivotal Phase 3 trial initiation for etripamil, which could significantly enhance its market position. The stock is currently priced at $1.16, and analysts have set a price target of $3, indicating a potential upside of over 150%. Additionally, the company reported a significant increase in prescriptions for its product, with Q2 2026 revenue reaching $559,000, a notable improvement from previous quarters. However, the main risk is the ongoing net losses, with a reported loss of $28.6 million in Q2 2026, which could impact future performance if not addressed.
估值指标
The current forward P/E ratio for Milestone Pharmaceuticals Inc (MIST) is 0.00, compared to its 5-year average forward P/E of -2.75.
Alphio AI Price Scenarios for MIST
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
事件时间线
资讯
8.509-03NewsfilterEverest Medicines to Lead Etripamil Commercialization in Greater China
9.009-03NASDAQ.COMMilestone Pharmaceuticals Secures Approval for Etripamil in China
9.008-21NASDAQ.COMMilestone Pharmaceuticals Initiates Pivotal Phase 3 Trial for Etripamil in AFib-RVR
- 2.008-21Newsfilter
Milestone Initiates Phase 3 ReVeRA-301 Trial for Etripamil in AFib-RVR
9.508-19NASDAQ.COMMilestone Pharmaceuticals Reports Strong Q2 Results with Significant Growth in CARDAMYST Prescriptions
MIST FAQ — answered by Alphio AI
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Milestone Pharmaceuticals Inc is a good buy right now due to its recent positive developments, including a pivotal Phase 3 trial initiation for etripamil, which could significantly enhance its market position. The stock is currently priced at $1.16, and analysts have set a price target of $3, indicating a potential upside of over 150%. Additionally, the company reported a significant increase in prescriptions for its product, with Q2 2026 revenue reaching $559,000, a notable improvement from previous quarters. However, the main risk is the ongoing net losses, with a reported loss of $28.6 million in Q2 2026, which could impact future performance if not addressed.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。